This is a routine conference presentation announcement with no new data. Monitor for the forthcoming press release on enrollment timing and site locations, which would be a more material catalyst. The BANYAN trial's progress is the key near-term pipeline event to watch.
Price Chart
Executive Summary
Tiziana Life Sciences announced a poster presentation on the Phase 2a BANYAN trial of intranasal foralumab in ALS at the ALS Nexus 2026 conference. The filing is a routine update on scientific conference participation with no new clinical data or financial information disclosed. The trial remains in operational start-up phase with enrollment timing to be announced later.
Key Facts
- Poster titled 'Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial' presented August 24, 2026 at ALS Nexus 2026.
- BANYAN is a 3:1 randomized, placebo-controlled, multicenter Phase 2a study evaluating intranasal foralumab in ALS.
- Trial is in operational start-up phase; enrollment timing and site locations to be provided in a future press release.
- Trial supported by grants from the ALS Association, Martha Olson-Fernandez Foundation, and ALS Bridge Foundation.
Financial Impact
No financial data disclosed in this filing.
Risk Factors
- No new clinical data was presented; the filing is purely an operational update.
- ALS trial is in early start-up phase with significant execution risk and no guarantee of successful enrollment or positive results.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-092792 |
| Document: 0001213900-26-092792-index-headers.html | 0001213900-26-092792 |
| Document: 0001213900-26-092792-index.html | 0001213900-26-092792 |
| Document: 0001213900-26-092792.txt | 0001213900-26-092792 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (−11.81%) |
Oct 16, 2026 9d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (+11.81%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8907 (−15.17%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8907 (−19.76%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 | awaiting T+20 | — | $0.8907 (−9.11%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8907 (−1.54%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8907 (−22.55%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8907 (−8.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers